# Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer

> **NCT00003257** · PHASE2 · UNKNOWN · sponsor: **Aventis Pharmaceuticals** · enrollment: 39 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** Ad5CMV-p53 gene

## Key facts

- **NCT ID:** NCT00003257
- **Lead sponsor:** Aventis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1998-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003257, "Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00003257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*